succinylacetone has been researched along with Anemia, Sickle Cell in 1 studies
succinylacetone: inhibitor of heme biosynthesis
4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fibach, E | 1 |
| Kollia, P | 1 |
| Schechter, AN | 1 |
| Noguchi, CT | 1 |
| Rodgers, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome[NCT00467610] | Phase 2 | 6 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to lack of efficacy.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00467610)
Timeframe: At 8 weeks from start of therapy
| Intervention | participants (Number) |
|---|---|
| Group 1 | 1 |
"Hematological improvement (HI)~Major:~HI-Erythroid:>2 g/dL rise in hemoglobin, or transfusion independence HI-Neutrophil: Absolute increase of >500/mm3, or >100% increase HI-Platelet: Absolute increase of >30,000, or transfusion independence~Minor:~HI-Erythroid:1 to 2 g/dL increase in hemoglobin or 50% decrease in transfusion dependence.~HI-P: For patients with pretreatment platelet count < 100,000/mm3, ≥ 50% increase with a net increase > 10,000/mm3 but < 30,000/mm3.~HI-N: For patients with pretreatment ANC < 1500/mm3, ≥ 100% increase, but < 500/mm3 increase." (NCT00467610)
Timeframe: 4 weeks after initiation of treatment with Panhematin
| Intervention | participants (Number) |
|---|---|
| Group 1 | 0 |
"Complete response(CR): <5% blasts in the bone marrow,with normal maturation of all cell lines, Hemoglobin >11 g/dL, neutrophils>1500/mm3 platelets>100,000/mm3.~Partial response (PR): >50% decrease in blasts, or less advanced IPSS than pretreatment value, same hematological parameters as in CR.~Stable disease (SD): No evidence of disease progression in bone marrow, stable peripheral blood counts failure: Increase in bone marrow blast percentage, progression to more advanced IPSS than pretreatment and worsening of cytopenias.~(Cheson, 2000)" (NCT00467610)
Timeframe: After 8 weeks of therapy with panhematin
| Intervention | Participants (Number) |
|---|---|
| Group 1 | 0 |
Number of patients with no adverse events. (NCT00467610)
Timeframe: participants were followed during therapy with panhematin, and up to six months post completion of therapy, average of 8 months.
| Intervention | participants (Number) |
|---|---|
| Group 1 | 6 |
1 other study available for succinylacetone and Anemia, Sickle Cell
| Article | Year |
|---|---|
Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin.
Topics: Anemia, Sickle Cell; beta-Thalassemia; Cell Division; Cells, Cultured; Drug Synergism; Erythroid Pre | 1995 |